CytoDyn Inc. (OTCMKTS:CYDY – Get Free Report) dropped 3.6% during mid-day trading on Monday . The stock traded as low as $0.2610 and last traded at $0.27. Approximately 2,516,042 shares traded hands during trading, an increase of 71% from the average daily volume of 1,468,975 shares. The stock had previously closed at $0.28.
CytoDyn Stock Performance
The company has a market capitalization of $342.82 million, a P/E ratio of -27.00 and a beta of 1.33. The firm has a 50 day moving average price of $0.29 and a two-hundred day moving average price of $0.29.
About CytoDyn
CytoDyn Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel immunotherapies. The company’s lead product candidate, leronlimab (PRO 140), is a humanized monoclonal antibody designed to block the CCR5 receptor, which plays a critical role in HIV infection and certain cancer pathways. CytoDyn is advancing leronlimab through multiple clinical trials targeting indications such as treatment-resistant HIV, metastatic triple-negative breast cancer, and other oncology and inflammatory conditions.
In its pursuit of regulatory approvals, CytoDyn has conducted Phase II and Phase III studies of leronlimab in people living with HIV who have experienced virologic failure on existing therapies.
See Also
- Five stocks we like better than CytoDyn
- Do not delete, read immediately
- INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
- How Long Will $1M Last in Retirement?
- [No Brainer Gold Play]: “Show me a better investment.”
- How to Capture a Slice of the Starlink IPO Buzz
Receive News & Ratings for CytoDyn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoDyn and related companies with MarketBeat.com's FREE daily email newsletter.
